Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Samidorphan

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Samidorphan: Patents, clinical trial progress, indications

Samidorphan is an investigational drug.

There have been 5 clinical trials for Samidorphan. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Schizophrenia, Alcohol Drinking, and Disease. The leading clinical trial sponsors are Alkermes, Inc. and [disabled in preview].

There are nineteen US patents protecting this investigational drug and one hundred and twenty-two international patents.

Recent Clinical Trials for Samidorphan
A Phase 1 Safety Study in Adults With SchizophreniaAlkermes, Inc.Phase 1
A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersAlkermes, Inc.Phase 1
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid UsersAlkermes, Inc.Phase 1

See all Samidorphan clinical trials

Clinical Trial Summary for Samidorphan

Top disease conditions for Samidorphan
Top clinical trial sponsors for Samidorphan

See all Samidorphan clinical trials

US Patents for Samidorphan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Samidorphan   Start Trial Compositions of buprenorphine and .mu. antagonists Alkermes Pharma Ireland Limited (Dublin, IE)   Start Trial
Samidorphan   Start Trial Opioid agonist antagonist combinations Alkermes Pharma Ireland Limited (Dublin, IE)   Start Trial
Samidorphan   Start Trial Methods for treating antipsychotic-induced weight gain Alkermes Pharma Ireland Limited (Dublin, IE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.